[PDF] Top 20 Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis

... infarction (AMI) which showed that the TESI seems to be a superior route of delivery [28]. In this research, the MSC infusion with TESI has a significant benefit to the end points, the infarct size and LVEF, while the ... See full document

... A systematic literature search was conducted using the PubMed, EMBASE, SpringerLink, Web of Science, and Cochrane Systematic Review databases to screen and identify all eligible studies published up ... See full document

... The estimated effect sizes of primary and secondary outcomes were determined by WMDs and 95% CIs. WMDs, an ideal measure for continuous data, were cal- culated by the mean (M), standard deviation (SD), and sample number ... See full document

... of stem cells have been demonstrated to be therapeutically valuable for treating various diseases, including auto- immune diseases, diabetes, myocardial infarction, and organ therapy rejection ...present ... See full document

... A meta-analysis conducted by Fold et al. has a failure to achieve remission in 724 ...of failure to achieve remission with 5-ASA compared with placebo in active UC was ...a ... See full document

... insulin therapy is difficult and has different chronic complications; therefore, finding a new standard treatment seems ...nors. Stem cell therapy with no restriction in primary source is ... See full document

... Cardiac stem cells have historically been an attractive therapeutic option due to their high angiogenic potential, balanced para- crine profile, and ability to differentiate into myocardial lineages when compared ... See full document

... with meta-analyses enables a more compre- hensive and objective assessment of scientific ...MSC therapy has not been used in the clinical treatment of patients with ...previous meta-analysis ... See full document

... expanded stem cells has been validated, this requiring a lot of cultivate time before implantation [26, ...of cell culture cross-contamination rather than true oncogenic transformation ... See full document

... MSC therapy during 5-year follow-up. In our analysis, the pooled rate of SAEs and SAEs related to SCT were 12% (95% CI 6–23) and 8% (95% CI 3–18), ... See full document

... group analysis to determine the optimized stem cell type and the proper transplantation type, but this approach leads to a reduction in the number of studies in each ...of meta-analysis ... See full document

... no meta-analysis was performed; instead, these data were pre- sented in a tabular ...a meta-analysis was conducted using a linear regression ...effects meta-analysis using the ... See full document

... proven to be noninferior to vancomycin for CDI treatment and more effective than vancomycin in reducing the rate of recurrence. These findings were not influenced by age stratification (age ,65 vs $65 years) in subgroup ... See full document

... There are a number of limitations to this review which need to be acknowledged. The majority of included studies were assessed as unclear risk of bias. This was largely owing to the lack of details, particularly ... See full document

... in meta-regression analyses included: dose of aerobic exer- cise (calculated as the overall number of weeks of training multiplied by the average number of sessions per week multiplied by the average duration of ... See full document

... combination therapy for patients with lung cancer remains ...a meta-analysis using PubMed, Embase, and ...this meta-analysis. Our results showed that ICI combination therapy was ... See full document

... the review reported a wide range of intervention durations, training frequency, session times and ...statistical analysis depended on extrapolated ... See full document

... Reported risk effect sizes and the statistical models used in each study were reviewed. Crude measures of effect with 95% CIs were extracted for each risk variable. Multiple within-study effects strati fi ed in subgroups ... See full document

... Because of the devastating course of the disease, and the lack of a definitive therapy for IPF other than transplanta- tion, there is a continuous need to find new options for IPF treatment. Although the ... See full document

... following exposure to oral GC therapy. The popula- tions of interest were patients with a diagnosis of PMR and/or GCA with no pre-existing diabetes (supple- mentary appendix 4). We assume that, if not otherwise ... See full document